Vitality Watch

Dossier pubmed observational 21-sep-2026
Human cohort, case-control, or epidemiological association

Functional Mobility as a Prognostic Marker in Geriatric Oncology: A Prospective Study Using Gait Speed.

Key claim: In chemotherapy-naive adults aged 65+, higher baseline usual-pace gait speed was independently associated with lower mortality among those with metastatic cancer, but not with PFS, non-metastatic survival, or grade ≥3 toxicity.

Abstract

: Functional impairment is common in older adults with cancer and may influence treatment outcomes. This study aimed to evaluate the prognostic value of objectively measured functional mobility, with gait speed as the primary analytical variable, for survival, treatment response, and chemotherapy-related toxicity in geriatric cancer patients.In this single-center prospective study, 102 patients aged 65 years and older who were chemotherapy-naive were enrolled. Before treatment initiation, functional mobility was assessed using a 3-m gait-speed test at the patient’s usual pace. Gait speed was analyzed primarily as a continuous variable; the sample-median cutoff was retained for secondary descriptive analyses, and 0.8 m/s was evaluated in a sensitivity analysis. Associations with survival, treatment response, and toxicity were evaluated using survival and regression analyses.The mean gait speed was 0.481 ± 0.176 m/s. Among patients with metastatic disease, higher continuous gait speed was associated with lower mortality in univariable analysis (HR = 0.752, 95% CI: 0.605-0.934,= 0.010) and after adjustment for age, sex, and ECOG performance status (adjusted HR = 0.647, 95% CI: 0.490-0.853,= 0.002). Gait speed was not significantly associated with metastatic PFS, non-metastatic OS or DFS, or grade ≥ 3 toxicity. The 0.8 m/s sensitivity analysis was limited by marked group imbalance.Higher baseline gait speed was associated with lower mortality in metastatic geriatric cancer patients, whereas statistically significant associations were not detected for PFS, non-metastatic survival outcomes, or grade ≥ 3 toxicity. These exploratory findings require validation in larger and more homogeneous cohorts.

Why this matters

In chemotherapy-naive adults aged 65+, higher baseline usual-pace gait speed was independently associated with lower mortality among those with metastatic cancer, but not with PFS, non-metastatic survival, or grade ≥3 toxicity.

Source

Link

Briefing card

Functional Mobility as a Prognostic Marker in Geriatric Oncology: A Prospective Study Using Gait Speed.
Stage: observational · pubmed · 21-sep-2026

In chemotherapy-naive adults aged 65+, higher baseline usual-pace gait speed was independently associated with lower mortality among those with metastatic cancer, but not with PFS, non-metastatic survival, or grade ≥3 toxicity.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.3390/medicina62091815

build build 880 · 2bcef25 · 2026-11-18